Magazin
2008-10-24
Paris (ots/PRNewswire) -
- GenOdyssee Has Received Notice of Allowance of European PatentApplication Covering Its Core Natural Evolution Technology Inventedin 2002, and Received Broad Product Applications Protection Rights toAll Cytokine Families
GenOdyssee (GO), a biotechnology company dedicated to thediscovery and development of improved 'next generation' human proteintherapeutics, announced today that it has received notice ofallowance from the European Patent Office of its Patent Applicationno.3 785 733.1 (PCT/EP03/13965) covering its core founding drugdiscovery technology process entitled "Method For Providing NaturalTherapeutic Agents With High Therapeutic Index" for applications toall therapeutic cytokine families.
The company pioneered the vision that natural evolution hascreated in the general population superior genetic variants of keyhuman protein therapeutic drugs as compared to the first wave ofreference protein therapeutic variants isolated and developed duringthe first biotech boom in the 80s, which currently constitutestandard of care.
"We have always believed that our technology has wide potentialin the industry for discovery of second generation products. Our IFNand EPO products have been granted IP in all major countries in whichwe filed a product patent application, including the EU and the USA.Our IP portfolio now extends to 53 patents and patent applications inmore than 19 countries. Importantly, the European patent office hasnow granted our technology broad product protection rights across allcytokine families. The granting of such broad IP product rights isrelatively unusual and has been achieved in this case becauseGenOdyssee successfully demonstrated successful application of itstechnology across multiple products in various cytokine families,"said Dr. David Brown, senior executive advisor for science & bus devto GenOdyssee.
"This confirms the uniqueness of our proprietary technology aswell as the global leadership of our company's platform in theprotein therapeutics optimization arena. There is potential to applyour technology to additional important classes of therapeuticcytokines such as Interleukins and CSFs," added Dr. Escary, chiefexecutive officer.
The company's first lead product is a novel, natural human IFNalpha variant protein called GEA007.1, a protein which is found inall major human populations It is a naturally occurring variant ofhuman IFN alpha 17, which incorporates an innovative amino acidsubstitution G45R that provides a novel positive charge together witha change in 3-D structure of the protein receptor binding site. Thebiochemical and structural modifications induced in the proteinbinding site provide for superior anti-HCV efficacy using theindustry gold standard replicon assay without significantly increasedtoxicity as demonstrated in Rhesus Monkeys compared to standards ofcare IFN alpha 2 molecules. GEA007.1 product patent applications havebeen granted in the EU and in the USA and are pending in anadditional 17 countries including Japan and emerging countries likeChina where HCV is also a major health problem.
Examination procedures by the international patent offices havenot revealed any relevant prior art to such product or to the naturalevolution technology invented by the company.
About GenOdyssee S.A.
GenOdyssee applies its proprietary population-genetics-based drugdiscovery approach using a proprietary DNA databank representative ofmore than 90% of the different ethnicities that constitute thecurrent human population, which is screened for natural geneticvariants of therapeutic proteins with superior pharmacologicalproperties. The company pioneered the vision that natural evolutionhas led to the generation in the current population of unpredictablemutations that confer superior or novel therapeutic status to knownimportant human therapeutic proteins. GenOdyssee's technology isprotected by the international patent application PCT/EP03/13965 andis the sole property of the company.
This technology has allowed GenOdyssee to identify in thepopulation a variety of innovative variations on existing key proteindrugs such as IFN alphas and EPO and to convert such variations intonovel drug candidates. The company's lead virology and immunotherapydrug candidates are GEA007.1 and GEA009.2, respectively targeted attreatments of HCV infection and cancer.
For more information about the company, please visit thecompany's website at http://www.genodyssee.com
About GEA007.1
GEA007.1 is a novel and first in man natural human IFN alphaprotein variant identified using the company's proprietary naturalevolution technology. It is found in all major human populations(Pacific, Iberian, Italian, Mexican, African, Caucasian, Chinese,Indo-Pakistan, Middle-Eastern, Japanese). GEA007.1 is a naturallyoccurring variant of human IFN alpha 17, which incorporates aninnovative amino acid substitution G45R that provides a novelpositive charge together with a change in 3-D structure of theprotein receptor binding site. The biochemical and structuralmodifications induced in the protein binding site provide forsuperior anti-HCV efficacy without increased toxicity of GEA007.1 ascompared to IFN alpha 2 which is the core agent of current standardof care. Long lasting second generation pegylated IFN alpha 2's havegiven major improvements in HCV therapy in combination withribavirin.
GEA007.1 is particularly positioned for use in HCV genotype 1which has become the predominant genotype worldwide and which is themost difficult to treat, as well as in patients infected with HCVgenotype 3 because of the following properties:
- Stronger anti-HCV activity in fresh human hepatocytes infectedwith HCV type 3 (genotype 3a) virus, in which GEA007.1 reduced HCVRNA to levels 3-4 fold lower than IFN alpha 2 drugs.
- Stronger anti-HCV activity in vitro in the HCV genotype 1bsubgenomic replicon assay (BM4-5 cells) as compared to IFN alpha 2.GEA007.1 exhibits a 7 fold superior inhibitory activity on HCVgenotype 1b RNA synthesis compared to IFN alpha 2.
- Viral clearance of HCV genotype 1b replicon subgenome wasobtained in BM4-5 cells after long-term administration (20 days) ofGEA007.1, as evidenced by elimination of HCV genotype 1b RNA (bothstrands) replicon genome. In contrast, HCV genotype 1b RNA (bothstrands) was still apparent in cells treated with IFN alpha 2 in sameconditions.
- No rebound of HCV genotype 1 replication after cessation ofGEA007.1 treatment. HCV subgenomic RNA remained undetectable after 5passages post-treatment in GEA007.1 treated cells, whereas a lowamount of positive strand HCV subgenomic RNA was maintained in IFNalpha 2 treated cells.
- Similar safety pharmacology in rhesus monkeys (Macacamulatta) to IFN alpha 2.
- Importantly, GEA007.1 is a natural human protein, whichmeans it is already functional and tolerated in man.
CONTACT: Dr. Jean-Louis Escary, CEO Tel: +33(0)616-416-857 Email: escary@genodyssee.com
ots Originaltext: GenOdyssee SAIm Internet recherchierbar: http://www.presseportal.de
Contact:CONTACT: Dr. Jean-Louis Escary, CEO, Tel: +33(0)616-416-857, Email: escary@genodyssee.com
GenOdyssee Receives Broad Product Applications Protection in EU for Founding Natural Evolution Technology
- GenOdyssee Has Received Notice of Allowance of European PatentApplication Covering Its Core Natural Evolution Technology Inventedin 2002, and Received Broad Product Applications Protection Rights toAll Cytokine Families
GenOdyssee (GO), a biotechnology company dedicated to thediscovery and development of improved 'next generation' human proteintherapeutics, announced today that it has received notice ofallowance from the European Patent Office of its Patent Applicationno.3 785 733.1 (PCT/EP03/13965) covering its core founding drugdiscovery technology process entitled "Method For Providing NaturalTherapeutic Agents With High Therapeutic Index" for applications toall therapeutic cytokine families.
The company pioneered the vision that natural evolution hascreated in the general population superior genetic variants of keyhuman protein therapeutic drugs as compared to the first wave ofreference protein therapeutic variants isolated and developed duringthe first biotech boom in the 80s, which currently constitutestandard of care.
"We have always believed that our technology has wide potentialin the industry for discovery of second generation products. Our IFNand EPO products have been granted IP in all major countries in whichwe filed a product patent application, including the EU and the USA.Our IP portfolio now extends to 53 patents and patent applications inmore than 19 countries. Importantly, the European patent office hasnow granted our technology broad product protection rights across allcytokine families. The granting of such broad IP product rights isrelatively unusual and has been achieved in this case becauseGenOdyssee successfully demonstrated successful application of itstechnology across multiple products in various cytokine families,"said Dr. David Brown, senior executive advisor for science & bus devto GenOdyssee.
"This confirms the uniqueness of our proprietary technology aswell as the global leadership of our company's platform in theprotein therapeutics optimization arena. There is potential to applyour technology to additional important classes of therapeuticcytokines such as Interleukins and CSFs," added Dr. Escary, chiefexecutive officer.
The company's first lead product is a novel, natural human IFNalpha variant protein called GEA007.1, a protein which is found inall major human populations It is a naturally occurring variant ofhuman IFN alpha 17, which incorporates an innovative amino acidsubstitution G45R that provides a novel positive charge together witha change in 3-D structure of the protein receptor binding site. Thebiochemical and structural modifications induced in the proteinbinding site provide for superior anti-HCV efficacy using theindustry gold standard replicon assay without significantly increasedtoxicity as demonstrated in Rhesus Monkeys compared to standards ofcare IFN alpha 2 molecules. GEA007.1 product patent applications havebeen granted in the EU and in the USA and are pending in anadditional 17 countries including Japan and emerging countries likeChina where HCV is also a major health problem.
Examination procedures by the international patent offices havenot revealed any relevant prior art to such product or to the naturalevolution technology invented by the company.
About GenOdyssee S.A.
GenOdyssee applies its proprietary population-genetics-based drugdiscovery approach using a proprietary DNA databank representative ofmore than 90% of the different ethnicities that constitute thecurrent human population, which is screened for natural geneticvariants of therapeutic proteins with superior pharmacologicalproperties. The company pioneered the vision that natural evolutionhas led to the generation in the current population of unpredictablemutations that confer superior or novel therapeutic status to knownimportant human therapeutic proteins. GenOdyssee's technology isprotected by the international patent application PCT/EP03/13965 andis the sole property of the company.
This technology has allowed GenOdyssee to identify in thepopulation a variety of innovative variations on existing key proteindrugs such as IFN alphas and EPO and to convert such variations intonovel drug candidates. The company's lead virology and immunotherapydrug candidates are GEA007.1 and GEA009.2, respectively targeted attreatments of HCV infection and cancer.
For more information about the company, please visit thecompany's website at http://www.genodyssee.com
About GEA007.1
GEA007.1 is a novel and first in man natural human IFN alphaprotein variant identified using the company's proprietary naturalevolution technology. It is found in all major human populations(Pacific, Iberian, Italian, Mexican, African, Caucasian, Chinese,Indo-Pakistan, Middle-Eastern, Japanese). GEA007.1 is a naturallyoccurring variant of human IFN alpha 17, which incorporates aninnovative amino acid substitution G45R that provides a novelpositive charge together with a change in 3-D structure of theprotein receptor binding site. The biochemical and structuralmodifications induced in the protein binding site provide forsuperior anti-HCV efficacy without increased toxicity of GEA007.1 ascompared to IFN alpha 2 which is the core agent of current standardof care. Long lasting second generation pegylated IFN alpha 2's havegiven major improvements in HCV therapy in combination withribavirin.
GEA007.1 is particularly positioned for use in HCV genotype 1which has become the predominant genotype worldwide and which is themost difficult to treat, as well as in patients infected with HCVgenotype 3 because of the following properties:
- Stronger anti-HCV activity in fresh human hepatocytes infectedwith HCV type 3 (genotype 3a) virus, in which GEA007.1 reduced HCVRNA to levels 3-4 fold lower than IFN alpha 2 drugs.
- Stronger anti-HCV activity in vitro in the HCV genotype 1bsubgenomic replicon assay (BM4-5 cells) as compared to IFN alpha 2.GEA007.1 exhibits a 7 fold superior inhibitory activity on HCVgenotype 1b RNA synthesis compared to IFN alpha 2.
- Viral clearance of HCV genotype 1b replicon subgenome wasobtained in BM4-5 cells after long-term administration (20 days) ofGEA007.1, as evidenced by elimination of HCV genotype 1b RNA (bothstrands) replicon genome. In contrast, HCV genotype 1b RNA (bothstrands) was still apparent in cells treated with IFN alpha 2 in sameconditions.
- No rebound of HCV genotype 1 replication after cessation ofGEA007.1 treatment. HCV subgenomic RNA remained undetectable after 5passages post-treatment in GEA007.1 treated cells, whereas a lowamount of positive strand HCV subgenomic RNA was maintained in IFNalpha 2 treated cells.
- Similar safety pharmacology in rhesus monkeys (Macacamulatta) to IFN alpha 2.
- Importantly, GEA007.1 is a natural human protein, whichmeans it is already functional and tolerated in man.
CONTACT: Dr. Jean-Louis Escary, CEO Tel: +33(0)616-416-857 Email: escary@genodyssee.com
ots Originaltext: GenOdyssee SAIm Internet recherchierbar: http://www.presseportal.de
Contact:CONTACT: Dr. Jean-Louis Escary, CEO, Tel: +33(0)616-416-857, Email: escary@genodyssee.com
GenOdyssee SA
| Preisvergleich Medikamente |
|
In Zusammenarbeit mit Medizinfuchs |
